Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Unraveling the Link Between Environmental Toxins and Lymphoma in Dogs

Lymphoma is a common cancer in dogs, but unlike human studies, which have associated the disease with environmental toxins, little is known about how it originates in dogs.

2 Jun 2023

Attacking the HTLV-1 Virus With the Help of Special Gene Scissors

HTLV-1 triggers aggressive forms of leukemia or an incurable spinal cord disease that leads to paralysis: the virus is the often ignored but no less insidious sibling of the HIV virus that causes AIDS and also belongs to the family of retroviruses.

6 Apr 2023

Role of Engineered E. coli in Sending Therapeutic Nanobodies to the Gut

Numerous bacterium types have taken up residence in humans. Currently, research is concentrated on genetically modifying these bacteria to increase their inherent therapeutic qualities.

5 Apr 2023

Stem cells must take out the trash to protect against age-related diseases

In humanity's ongoing quest for the elixir of life, the science keeps pointing to stem cells. Research increasingly shows that maintaining stem cell fitness promotes a long healthspan, and new findings show keeping stem cells clean and tidy is an integral step.

22 Mar 2023

New study pinpoints key source of T cell "exhaustion"

Custom-made to attack cancer cells, CAR T-cell therapies have opened a new era in the treatment of human cancers, particularly, in hematologic malignancies.

21 Mar 2023

Gut microbiome may modulate the efficacy of CAR-T cell cancer immunotherapy

Scientists from German Cancer Research Center (DKFZ), together with colleagues from Germany, Israel, and the USA, have found that the gut microbiome may modulate the efficacy of CAR-T cellular immunotherapy CAR-T cells in patients with B cell lymphomas.

14 Mar 2023

Understanding the relationship between gut microbiome and CAR T-cell therapy response

Microorganisms live in or on almost every part of the human body and play an important role in the regulation of normal human processes. As a result, changes in the number or type of microorganisms, also known as the microbiome, can contribute to disease and altered responses to therapy, including cancer treatment.

14 Mar 2023

The mechanism behind fruit fly germ cells forming ring canals

Cell division is the process through which the majority of cells in the bodies of living beings duplicate their contents and physically split into new cells.

10 Mar 2023

Herpesvirus infection boosts host cellular immunity: Study

A new editorial was published in Genes & Cancer on January 19th, 2023, entitled, "Severe herpesvirus infection beats adult T-cell leukemia/lymphoma."

27 Feb 2023

Whole genome sequencing might help better assess tumor evolution

To develop the most efficacious, personalized treatment plans for patients with Hodgkin lymphoma or other cancers, researchers and clinicians must first understand the genetic changes that cause cancer to develop.

23 Feb 2023

MD Anderson and Replay launch new company pioneering T cell receptor NK cell therapies

The University of Texas MD Anderson Cancer Center and Replay today announced the launch of Syena, a new oncology-focused product company pioneering T cell receptor (TCR) natural killer (NK) cell therapies.

15 Feb 2023

Analyzing the immune microenvironment around Hodgkin lymphoma tumors

The most detailed study of Hodgkin lymphoma, a type of blood cancer, has offered considerable insight into what tumor cells must do to sustain. The Wellcome Sanger Institute discovered that cancer cells utilize signals to attract specific types of immune cells and direct them not to attack.

15 Feb 2023

Protein that facilitates cancer-causing viruses dodge the immune system

Numerous cancers have been related to the viruses Epstein-Barr virus (EBV) and Kaposi sarcoma-associated herpesvirus (KSHV). For the first time, UNC School of Medicine researchers have shown that these viruses elude the innate immune response by using a human protein called barrier-to-autointegration factor 1, or BAF, which enables the viruses to propagate and cause disease.

7 Feb 2023

Cedars-Sinai's Stem Cell and Bone Marrow Transplant Program recognized with two hallmarks of quality

The Stem Cell and Bone Marrow Transplant Program at Cedars-Sinai Cancer was recently recognized with two important hallmarks of quality: official accreditation for CAR T-cell therapy, and a third year in a row ranking among the top adult bone marrow transplant programs in the U.S.

31 Jan 2023

Novel blood biomarker predicts a favorable response to CART cell therapy

A MedUni Vienna research group identified a particularly potent biomarker for clinical response to CAR-T cell therapy, establishing the conditions for the most effective use of this innovative therapy for lymphoma treatment.

11 Jan 2023

Major development in re-treatment with CAR T therapy

At the American Society of Hematology (ASH) Annual Meeting in 2022 (Abstract 2016), researchers from the Abramson Cancer Center at the University of Pennsylvania presented preliminary findings from an ongoing Phase I clinical trial demonstrating effective re-treatment with CAR T cell therapy for patients whose cancers relapsed after prior CAR T therapy.

12 Dec 2022